US2010286060A1PendingUtilityA1

Specific binding agents of human angiopoeitin-2

56
Assignee: AMGEN INCPriority: Oct 11, 2001Filed: Mar 23, 2010Published: Nov 11, 2010
Est. expiryOct 11, 2021(expired)· nominal 20-yr term from priority
Inventors:Jonathan Daniel OlinerHosung Min
A61P 9/14A61P 9/00A61P 9/10A61P 7/04A61P 43/00A61P 29/00A61P 35/00A61P 27/02A61P 3/04A61P 19/02C07K 7/08C07K 14/001A61P 19/08C07K 2317/73A61K 47/68C07K 14/00C07K 2319/32C07K 2317/92A61P 19/00A61P 17/06C07K 7/06C07K 16/22A61P 11/06C07K 2319/30A61P 15/00C07K 7/00
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.

Claims

exact text as granted — not AI-modified
1 - 117 . (canceled) 
     
     
         118 . A polypeptide that specifically binds to Ang2, said polypeptide comprising an amino acid sequence of SEQ ID NO: 4 with at least one of: up to 2 amino acid substitutions, up to 1 deletion, or up to 1 insertion therein, wherein said polypeptide has at least one substitution, insertion or deletion,
 and physiologically acceptable salts thereof.   
     
     
         119 . A polypeptide according to  claim 118 , wherein said polypeptide comprises an amino acid sequence of SEQ ID NO: 4 with 1 or 2 amino acid substitutions therein. 
     
     
         120 . A polypeptide according to  claim 118 , wherein said polypeptide comprises an amino acid sequence of SEQ ID NO: 4 with 1 or 2 conservative amino acid substitutions therein. 
     
     
         121 . A polypeptide according to  claim 118 , wherein said polypeptide comprises an amino acid sequence of SEQ ID NO: 4, with 1 conservative amino acid substitution therein. 
     
     
         122 . A polypeptide according to  claim 118 , wherein said polypeptide comprises an amino acid sequence of SEQ ID NO: 4 with 1 deletion therein. 
     
     
         123 . A polypeptide according to  claim 118 , wherein said polypeptide comprises an amino acid sequence of SEQ ID NO: 4 with 1 insertion therein. 
     
     
         124 . A polynucleotide encoding a polypeptide according to  claim 118 . 
     
     
         125 . The polynucleotide according to  claim 124 , wherein the polypeptide is encoded as set forth in SEQ ID NO: 46. 
     
     
         126 . An expression vector comprising the polynucleotide of  claims 124 . 
     
     
         127 . A host cell comprising the expression vector of  claim 126 . 
     
     
         128 . The host cell according to  claim 127  wherein the cell is an  E. coli  cell. 
     
     
         129 . A method of inhibiting angiogenesis in a mammal comprising administering a therapeutically effective amount of the polypeptide according to  claim 118 . 
     
     
         130 . A method of inhibiting tumor growth characterized by undesired angiogenesis in a mammal comprising administering a therapeutically effective amount of the polypeptide according to  claim 118 . 
     
     
         131 . A method of treating cancer in a mammal comprising administering a therapeutically effective amount of the polypeptide according to  claim 118  and a chemotherapeutic agent. 
     
     
         132 . A polypeptide that specifically binds to Ang-2, said polypeptide comprising the amino acid sequence of SEQ ID NO: 25 with at least one of up to 4 amino acid substitutions, up to 1 insertion or up to 1 deletion therein, wherein said polypeptide has at least one substitution, insertion or deletion,
 and physiologically acceptable salts thereof.   
     
     
         133 . A polypeptide according to  claim 132 , wherein said polypeptide comprises an amino acid sequence of SEQ ID NO: 25 with 1 or 2 amino acid substitutions or 1 deletion or 1 insertion therein. 
     
     
         134 . A polypeptide according to  claim 132 , wherein said polypeptide comprises an amino acid sequence of SEQ ID NO: 25 with 1 or 2 amino acid substitutions therein. 
     
     
         135 . A polypeptide according to  claim 132 , wherein said polypeptide comprises an amino acid sequence of SEQ ID NO: 25 with 1 or 2 conservative amino acid substitutions therein. 
     
     
         136 . A polypeptide according to  claim 132 , wherein said polypeptide comprises an amino acid sequence of SEQ ID NO: 25 with 1 conservative amino acid substitution therein. 
     
     
         137 . A polypeptide according to  claim 132 , wherein said polypeptide comprises an amino acid sequence of SEQ ID NO: 25 with 1 deletion therein. 
     
     
         138 . A polypeptide according to  claim 132 , wherein said polypeptide comprises an amino acid sequence of SEQ ID NO: 25 with 1 insertion therein. 
     
     
         139 . The polypeptide according to  claim 132 , wherein the Fc in SEQ ID NO: 25 is the Fc of a human IgG1. 
     
     
         140 . The polypeptide according to  claim 139 , wherein the amino acid sequence of the Fc in SEQ ID NO: 25 is SEQ ID NO: 60. 
     
     
         141 . A method of inhibiting angiogenesis in a mammal comprising administering a therapeutically effective amount of the polypeptide according to  claim 133 . 
     
     
         142 . A method of inhibiting tumor growth characterized by undesired angiogenesis in a mammal comprising administering a therapeutically effective amount of the polypeptide according to  claim 133 . 
     
     
         143 . A method of treating cancer in a mammal comprising administering a therapeutically effective amount of the polypeptide according to  claim 133  and a chemotherapeutic agent.

Join the waitlist — get patent alerts

Track US2010286060A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.